Diagnostic and Management of Acquired Hemophilia
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 7394
Special Issue Editor
Interests: hemophilia A and B; Von Willebrand disease; rare coagulation disorders; antipholipid antibodies (lupus anticoagulant, anticardiolipin antibodies); deep vein thrombosis and pulmonary embolism; venous thromboembolism; arterial thrombosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Acquired hemophilia A is a rare bleeding disorder caused by a spontaneous development of autoantibodies against the coagulation factor VIII in males and females with a previously normal hemostasis.
Morbidity and mortality associated with AHA are high, especially in elderly patients with severe co-morbidities.
The use of hemostatic agents to control bleeding and immunosuppressive therapy to eliminate the inhibitor are the gold standard of the treatment.
Hemostatic therapy regimens involve recombinant activated factor VII (rVIIa) and/or activated prothrombin concentrate complex (aPCC) and, more recently, recombinant porcine FVIII (rpFVIII), but it is not clear how they should be chosen to obtain the best control of bleeding.
Steroids, cyclophosphamide, or rituximab are used as immunosuppressive therapy; therefore, it would be important to use these drugs alone or combined in different ways depending on the cause of acquired hemophilia.
Laboratory diagnosis can be complicated, and several limitations and pitfalls exist in the assays used to diagnose AHA.
This Special Issue in “Diagnostic and Management of Acquired Hemophilia” aims to provide an overview of current laboratory diagnosis and strategy of treatment.
Full research papers, communications, and review articles are welcome to give answers to the many questions and concerns related to this field.
Dr. Ezio Zanon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acquired hemophilia A
- FVIII
- inhibitor
- autoantibody
- assay methods
- recombinant porcine FVIII
- recombinant activated FVII
- activated prothrombin complex concentrate
